Aquestive(AQST) Zacks Investment Research·2024-03-22 23:06Company Performance - Aquestive Therapeutics (AQST) closed at 4.38, showing no change from the previous session, outperforming the S&P 500 which lost 0.14% [1] - The stock has increased by 66.54% over the past month, leading the Medical sector's gain of 0.88% and the S&P 500's gain of 5.34% [1] - The upcoming earnings disclosure is anticipated, with an expected EPS of -0.09, reflecting a 181.82% decline year-over-year, while revenue is projected at 0.38 per share and revenue of $50.85 million, indicating year-over-year changes of -192.31% for earnings and +0.52% for revenue [2] - Recent changes in analyst estimates are crucial as they reflect short-term business trends, with upward revisions indicating analysts' positive outlook on the company's operations [2] Zacks Rank and Industry Position - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), shows that AQST currently holds a Zacks Rank of 3 (Hold) [3] - The Medical - Drugs industry, to which AQST belongs, has a Zacks Industry Rank of 145, placing it in the bottom 43% of over 250 industries [3] - The Zacks Industry Rank measures the strength of industry groups, with top-rated industries outperforming the bottom half by a factor of 2 to 1 [3]